学術雑誌
学会発表
    （最終更新日：2026-07-28 13:32:10）
  ミゾグチ　シンスケ   MIZOGUCHI Shinsuke
  溝口　晋輔
   所属   その他 その他  泌尿器科学講座　泌尿器科学分野
   職種   臨床修練生
■ 学術雑誌
1. 原著　 Real-world outcomes of third-line systemic therapy after immune checkpoint inhibitor combinations and subsequent VEGFR-TKIs in advanced renal cell carcinoma. 2026/06/05
2. 原著　 Non-clear cell renal cell carcinoma has an immune-cold phenotype that affects response to immune checkpoint inhibitors. 2026/05/04
3. その他　 Safety and efficacy of enfortumab vedotin for metastatic urothelial carcinoma in over 80 years old patients: Multi-center retrospective study in JAPAN. 2026/05 Link
4. 原著　 Impact of first-line dual immuno-oncology combination therapy versus immuno-oncology plus tyrosine kinase inhibitor on outcomes of second-line VEGFR-TKI in advanced RCC: a real-world multi-institutional analysis. 2026/03
5. 原著　 Impact of starting dose of tyrosine kinase inhibitors on outcomes following combination therapy of immune checkpoint inhibitors with tyrosine kinase inhibitors for previously untreated advanced renal cell carcinoma. 2026/01
全件表示(24件)
■ 学会発表
1. Safety and efficacy of enfortumab vedotin for metastatic urothelial carcinoma in over 80 years old patients: Multi-center retrospective study in JAPAN （ポスター掲示，一般） 2026/05/16
2. Experience of adjuvant pembrolizumab in patients with renal cell carcinoma: An initial report using short-term follow-up data. （ポスター掲示，一般） 2026/04/23
3. 腎細胞がんに対するfirst-line IO-TKI治療の3年観察期間リアルワールドデータ （口頭，一般） 2026/04/23
4. Association between enfortumab vedotin and renal function in metastatic urothelial carcinoma:A multicenter retrospective study in Japan. （口頭，一般） 2025/10/25
5. 80歳以上の転移性尿路上皮癌患者に対するパドセブの安全性と有効性について （口頭，一般） 2025/10/17
全件表示(40件)